Direct Stenting is Better (Debate Session) 동아의대 김 무 현.

Slides:



Advertisements
Similar presentations
PCI Unmet Clinical Needs
Advertisements

Www. Clinical trial results.org  Major Endpoints: Death, MI, stent thrombosis, TLR, TVR, MACE, and CKMB >3x nl  Major Endpoints: Death, MI, stent thrombosis,
BIFURCATION LESIONS Dr. Tahsin.N
Distal Protection: PRIDE, CAPTIVE Symbiot III, AiMI Dr James Cotton MD MRCP Heart and Lung Centre Wolverhampton.
FFR vs Angiography for Multivessel Evaluation
Rotablation or Balloon Immediate and 6 month results of a trial in patients with chronic total coronary occlusion Layth A. Mimish, M. Bakhshi, J. Buraiki,
Optimal Stent Expansion and Optimization
2 Year Clinical Outcomes from the Pivotal RESOLUTE US Study Laura Mauri MD, MSc on behalf of the RESOLUTE US Investigators Brigham and Women’s Hospital.
29th ANNUAL SCIENTIFIC SESSIONS – SCA&I
University Medical Center Groningen Thrombus aspiration during primary PCI FZ Thrombus Aspiration during Percutaneous coronary intervention in Acute.
DIABETES trial P Jiménez-Quevedo, M Sabaté, DJ Angiolillo, JA Gómez-Hospital, R Hernández-Antolín, J Goicolea, F Alfonso, C Bañuelos, J Escaned, R Moreno,
M.Unverdorben; TCT Problem The treatment of stenoses of small coronary arteries (SVD) and of restenoses after stent deployment (ISR) still show.
As presented by Patrick W. Serruys, MD, PhD, FACC Principal Investigator Thoraxcentre - Erasmus University Rotterdam, The Netherlands PISCES Paclitaxel.
Conventional Stenting Following Predilation and/or Debulking Is Better Than Direct Stenting Myeong-Ki Hong, MD, PhD Asan Medical Center, Seoul, Korea.
Proxis Proximal embolic protection in saphenous vein graft and infarct PCI Dan Blackman Leeds General Infirmary Advanced Angioplasty 2006.
Meredith ● EVOLVE Primary Endpoint ● TCT 2011 ● San Francisco, CA Slide 1 Meredith ● EVOLVE overview ● TCT 2010 ● Washington, DC Slide 1 Clinical and Angiographic.
TRI vs TFI in STEMI Shenyang Northern Hospital Wang Shouli Han Yalin.
Richard Melsheimer Director, Medical Affairs Europe Centocor Eli Lilly and Company Coordinated Use of ReoPro and Drug Eluting Stents: Rationale and Evidence.
The REALITY Study Results. REALITY Study Design The REALITY Study : Prospective randomized clinical trial to evaluate the safety and efficacy of CYPHER®
Rapamycin- and Paclitaxel-Eluting Stents With Identical Biodegradable Polymeric Coating and Design Trial Presented at The American College of Cardiology.
Tetra Randomized European Direct Stenting Study (TRENDS)
Treatment of In-Stent Restenosis by Paclitaxel Coated PTCA Balloons Presented at The American Heart Association Scientific Session 2006 Presented by Dr.
SIROLIMUS-ELUTING STENTS EFFECTIVELY INHIBIT NEOINTIMAL PROLIFERATION AS COMPARED TO BARE METAL STENTS IN DISEASED SAPHENOUS VEIN GRAFTS: 6-month IVUS.
A Randomized Comparison of Everolimus-­ Eluting Absorb Bioresorbable Vascular Scaffolds vs. Everolimus-Eluting Metallic Stents: One-Year Angiographic and.
FRONTIER Registry The Guidant MULTI-LINK FRONTIER ™ Coronary Stent System for the Treatment of Pts with Native De Novo or Restenotic Bifurcation Coronary.
Slow-rate release polymer-based paclitaxel- eluting stent compared with bare stent in patients with single complex coronary lesions TAXUS V Presented at.
A Prospective, Randomized Trial Evaluating a Paclitaxel-Eluting Balloon in Patients TReated with Endothelial Progenitor Cell CapTuring Stents for De Novo.
ROTAXUS A Prospective, Randomized Trial of High-Speed Rotational Atherectomy Prior to Paclitaxel-Eluting Stent Implantation in Complex Calcified Coronary.
Endeavor 4: A Randomized Comparison of a Zotarolimus- Eluting Stent and a Paclitaxel- Eluting Stent in Patients with Coronary Artery Disease Martin B.
Www. Clinical trial results.org Cypher sirolimus-eluting stent Primary Endpoint:  In-stent and late lumen loss at 9 months (determined by QCA) Secondary.
Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial Myeong-Ki.
ISAR-CABG Objective To compare the efficacy of DES with BMS in a randomized trial powered for clinical events Sample 610 patients with de novo SVG lesions.
Distal protection devices Dr Donald Baim Director, Center for Innovative Minimally Invasive Therapy Brigham & Women’s Hospital Boston, MA.
The SAFER Trial Evaluation of the Clinical Safety and Efficacy of the PercuSurge GuardWire in Saphenous Vein Graft Intervention As presented at TCT 2000.
Is there any role for intravascular ultrasound in bifurcation lesions? Giuseppe Biondi-Zoccai, MD University of Turin, Turin, Italy.
A Prospective, Randomized Trial of a Paclitaxel coated Balloon vs. uncoated Balloon Angioplasty in Patients with Drug- Eluting Stent Restenosis PEPCAD-DES.
Date of download: 6/25/2016 Copyright © The American College of Cardiology. All rights reserved. From: Implantation of a Drug-Eluting Stent With a Different.
Northeast Georgia Heart Center State of the Art Review: Bypass graft Interventions J. Jeffrey Marshall, MD, FSCAI Past President SCAI, Director.
Date of download: 7/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: Clinical restenosis after coronary stenting: perspectives.
Philippe Généreux, MD for the Tryton Bifurcation Trial Investigators Columbia University Medical Center Cardiovascular Research Foundation New York City.
End points in PTCA trials. A successful angioplasty is defined as the reduction of a minimum stenosis diameter to
Trial to Assess the Use of the Cypher Stent in Acute Myocardial Infarction Treated with Balloon Angioplasty (TYPHOON) Trial Presented at The American College.
Intravascular ultrasound (IVUS) in the treatment of long and diffuse lesions– summary of key articles Prepared by Radcliffe Cardiology 21 November2016.
Clinical Usefulness of Post-Stenting FFR
From: Paclitaxel-Eluting Stents vs Vascular Brachytherapy for In-Stent Restenosis Within Bare-Metal StentsThe TAXUS V ISR Randomized Trial JAMA. 2006;295(11):
(DES)+BVS +DCB for long diffuse LAD disease
LONG-DES II Trial Randomized Comparison of the Efficacy of Sirolimus-Eluting Stent Versus Paclitaxel-Eluting Stent in the Treatment of Long Native Coronary.
TAXUS IV Trial Slow-rate release polymer-based paclitaxel-eluting stent compared with bare stent in patients with single de novo coronary lesions Presented.
Subintimal Tracking and Reentry for CTO STAR Method
Stenting of Coronary Arteries in Non Stress/Benestent Disease
SIRIUS Trial: Diameter Restenosis
AcoArt I Trial design: Patients with femoropopliteal artery disease were randomized to paclitaxel-coated balloon angioplasty (n = 100) vs. standard peripheral.
TAXUS II and IV: two-year follow-up
Angiography-guided PCI
BBK II Trial design: Patients undergoing a two-stent approach for a de novo bifurcation lesion were randomized in a 1:1 fashion to either culotte stenting.
American College of Cardiology Presented by Dr. Stephan Windecker
3-Year Clinical Outcomes From the RESOLUTE US Study
Presented at ACC 2003 Late Breaking Clinical Trials
Randomized Comparison in the Setting of Acute MI
SIRIUS: A U.S. Multicenter, Randomized, Double-Blind Study of the SIRolImUS-Eluting Stent in De Novo Native Coronary Lesions Presented at TCT 2002.
Bifurcation Disease: Simulation Training Curriculum
Main branch restenosis at 1 year
Role of Stenting in Acute MI: PAMI Stent Pilot Trial
SMART-STRATEGY Trial design: Patients with a bifurcation coronary lesion were randomized to a conservative strategy (n = 128) vs. an aggressive strategy.
Presented at TCT 2006.
Martin B. Leon, David R. Holmes, Dean J. Kereiakes, Jeffrey J
Maintenance of Long-Term Clinical Benefit with
Sirolimus Stent vs. Bare Stent in Acute Myocardial Infarction Trial
The American College of Cardiology Presented by Dr. A. Abazid
TYPHOON Trial Trial to Assess the Use of the Cypher Stent in Acute Myocardial Infarction Treated with Balloon Angioplasty (TYPHOON) Trial Presented at.
Presentation transcript:

Direct Stenting is Better (Debate Session) 동아의대 김 무 현

Direct Stenting(without pre-dilatation) Direct PTCA = Primary PTCA Direct Stenting ≠ Primary stenting Direct Stenting = Stenting without pre-dilation

Possible Advantage of Direct Stenting Reduce cost Reduce procedure time Reduce radiation exposure Reduce injury to the vessel wall Reduce distal embolization in SVG Improve coronary flow in AMI patient

Randomized Trial of Direct Stenting PREDICT Trial – Baim DS et al, JACC 2001 BET Trial – Carrie D et al, AJC 2001 DIRECT Trial – Brito FS et al, AJC 2002 AMI Patient – Loubeyre C et al, JACC 2002

PRE-Dilatation vs Direct Stenting In Coronary Treatment 399 patients with S670 stents Modest (10%) saving of fluoroscopic time, contrast use and a decrease in use of balloob use No reduction in late restenosis PREDICT Trial Baim DS et al, Am J Cardiol 2001;88:1364-9

Procedure time(min)33.2± ±16.5 Fluoroscopy time(min)9.2 ± ±8.1 Contrast use(ml)154 ±86169 ±82 Balloon use0.56 ± ±0.62 * Stent/lesion1.20 ± ±0.42 Single stent84%(168/201)84%(170/203) Acute Procedural Results (PREDICT) * P < 0.001

Direct Pre-dilatation Available for analysis162/201(81%)163/203(80%) Reference vessel2.85± ±0.46 In-stent Minimal lumen diameter1.95 ± ±0.73 Diameter stenosis31.6 ± ±22 Binary restenosis20.4(33/162)20.9(34/163) Loss index0.51 ± ±0.32 Angiographic Follow-up (PREDICT)

Event Free Survival (DIRECT Study) Brito FS et al, Am J Cardiol 2002;89: (P=0.0002) N=411

Direct Stenting in AMI (n=206) Reduce the incidence of no-reflow or distal embolization Early ST-segment elevation resolution >>> Direct stenting in AMI can prevents microvascular damage and may improve myocardial perfusion. Loubeyre C et al, JACC 2002;39:15-21

In-hospital Clinical Outcome(AMI) p=0.36p=0.89 p=0.28p=0.99 p=0.55 Loubeyre C et al, JACC 2002;39:15-21

Comparison of Randomized Trial No SR PT Contrast Cost RR AE Flow PREDICT 40091%--+-- * DIRECT 41197%--+*- * BET 33886% + ++*- * AMI(Loubeyre)20692% **+*- +

Months from discharge Event-free survival(%) (death/MI/revascularization) Immediate and Late Outcomes after Direct Stenting Wilson SH et al, JACC 2000;35:937-43

Potential Direct Stenting Exclusion Extensive calcification Total or subtotal occlusion Severe lesion angulation Proximal vessel tortuosity Ostial or bifurcation lesion Suboptimal guide support

Possible Disadvantages May increase cost and procedure time Failure to deliver stent Failure to remove undelivered stent Stent selection difficulty : Size and length Unpredictable undilatable lesion

Direct Stenting in SVG Shorter duration of procedure Lower radiation exposure Similar clinical outcome May decrease distal embolization

IVUS guided DS in Native Coronary Artery CS DS p Procedural Success, % In-Hospital MACE, % One Year TLR, % One Year MACE, % Ahmed JM, et al, Eur Heart J 2001(supp)

DS P & S p Procedural success(%) In-hospital MACE(%) Non-Q wave MI (%) one year (%) one year (%) IVUS guided DS in SVG Ahamed JM et al, Eur H J(supp) 2001

DS B & S p Angiographic Complication(%) No. of Stent NS CK-MB Elevation Final IVUS Lumen CSA Final IVUS Lumen diameter one year (%) IVUS guided DS in SVG Abizaid AS et al, JACC(supp) 2002

Should every eligible lesion undergo direct stenting ? It can reduce cost, contrast and procedure time It has same restenosis, dissection and acute complication rate. >>> Why not if we select appropriate lesion. ( Not in Korea !!!! )

But we have to be careful !!! When angiograpically overlooked fibrotic or calcific lesion is present When vessel is tortuous When a 5 Fr guiding catheter is used